J. Clin. Lab. Anal. volume 29, issue 2, P106-111 2014 DOI: 10.1002/jcla.21736 View full text
|
|
Share
Kei Ohnuma, Tatsuhiko Saito, Ryou Hatano, Osamu Hosono, Satoshi Iwata, Nam H. Dang, Hiroki Ninomiya, Chikao Morimoto

Abstract: These data strongly suggest that new commercial assays for sCD26 plasma levels need detailed evaluation and validation with samples from clinically well-characterized patients, and results obtained from these newer assays should be compared to those obtained from well-established in-house assays such as our assay or other validated sCD26 ELISA assays.